Cargando…

Radiohybrid Ligands: A Novel Tracer Concept Exemplified by (18)F- or (68)Ga-Labeled rhPSMA Inhibitors

When we critically assess the reason for the current dominance of (68)Ga-labeled peptides and peptide-like ligands in radiopharmacy and nuclear medicine, we have to conclude that the major advantage of such radiopharmaceuticals is the apparent lack of suitable (18)F-labeling technologies with proven...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wurzer, Alexander, Di Carlo, Daniel, Schmidt, Alexander, Beck, Roswitha, Eiber, Matthias, Schwaiger, Markus, Wester, Hans-Jürgen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Society of Nuclear Medicine 2020
Materias:	Theranostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7198388/ https://www.ncbi.nlm.nih.gov/pubmed/31862804 http://dx.doi.org/10.2967/jnumed.119.234922

Ejemplares similares

Synthesis and Preclinical Characterization of the PSMA-Targeted Hybrid Tracer PSMA-I&F for Nuclear and Fluorescence Imaging of Prostate Cancer
por: Schottelius, Margret, et al.
Publicado: (2019)

Preclinical biodistribution and dosimetry and human biodistribution comparing (18)F-rhPSMA-7 and single isomer (18)F-rhPSMA-7.3
por: Knorr, Karina, et al.
Publicado: (2022)

Preclinical comparison of four [(18)F, (nat)Ga]rhPSMA-7 isomers: influence of the stereoconfiguration on pharmacokinetics
por: Wurzer, Alexander, et al.
Publicado: (2020)

Monosodium Glutamate Reduces (68)Ga-PSMA-11 Uptake in Salivary Glands and Kidneys in a Preclinical Prostate Cancer Model
por: Rousseau, Etienne, et al.
Publicado: (2018)

Automated synthesis of [(18)F]Ga-rhPSMA-7/ -7.3: results, quality control and experience from more than 200 routine productions
por: Wurzer, Alexander, et al.
Publicado: (2021)

Detection Efficacy of (18)F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy
por: Giesel, Frederik L., et al.
Publicado: (2019)

Synthesis and Preclinical Evaluation of (177)Lu-Labeled Radiohybrid PSMA Ligands for Endoradiotherapy of Prostate Cancer
por: Wurzer, Alexander, et al.
Publicado: (2022)

(68)Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers
por: Giesel, Frederik L., et al.
Publicado: (2019)

Diagnostic Accuracy of (18)F-PSMA-1007 PET/CT Imaging for Lymph Node Staging of Prostate Carcinoma in Primary and Biochemical Recurrence
por: Sprute, Katharina, et al.
Publicado: (2021)

Head-to-Head Comparison of (68)Ga-Prostate-Specific Membrane Antigen PET/CT and Ferumoxtran-10–Enhanced MRI for the Diagnosis of Lymph Node Metastases in Prostate Cancer Patients
por: Schilham, Melline G.M., et al.
Publicado: (2021)

FAPI-74 PET/CT Using Either (18)F-AlF or Cold-Kit (68)Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients
por: Giesel, Frederik L., et al.
Publicado: (2021)

A Prospective Study on (18)F-DCFPyL PSMA PET/CT Imaging in Biochemical Recurrence of Prostate Cancer
por: Rousseau, Etienne, et al.
Publicado: (2019)

Pitfalls in PSMA imaging: [(18)F]rhPSMA-7-PET/CT reveals presence of chrondrosarcoma
por: Feuerecker, B., et al.
Publicado: (2021)

A rare case of polyostotic fibrous dysplasia detected on (18)F-rhPSMA-7 PET/CT
por: Wang, Hui, et al.
Publicado: (2020)

Effect of Carbohydration on the Theranostic Tracer PSMA I&T
por: Schmidt, Alexander, et al.
Publicado: (2018)

Synergistic Effect of a Mesothelin-Targeted (227)Th Conjugate in Combination with DNA Damage Response Inhibitors in Ovarian Cancer Xenograft Models
por: Wickstroem, Katrine, et al.
Publicado: (2019)

Efficacy and Safety of High-Specific-Activity (131)I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma
por: Pryma, Daniel A., et al.
Publicado: (2019)

Imaging DNA Damage Repair In Vivo After (177)Lu-DOTATATE Therapy
por: O’Neill, Edward, et al.
Publicado: (2020)

Enhancement of (211)At Uptake via the Sodium Iodide Symporter by the Addition of Ascorbic Acid in Targeted α-Therapy of Thyroid Cancer
por: Watabe, Tadashi, et al.
Publicado: (2019)

Development of Fibroblast Activation Protein–Targeted Radiotracers with Improved Tumor Retention
por: Loktev, Anastasia, et al.
Publicado: (2019)

Bone Marrow Absorbed Doses and Correlations with Hematologic Response During (177)Lu-DOTATATE Treatments Are Influenced by Image-Based Dosimetry Method and Presence of Skeletal Metastases
por: Hagmarker, Linn, et al.
Publicado: (2019)

Addition of (131)I-MIBG to PRRT ((90)Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors
por: Bushnell, David L., et al.
Publicado: (2021)

Preclinical Characterization of the Radioimmunoconjugate (111)In or (90)Y-FF-21101 Against a P-Cadherin–Expressing Tumor in a Mouse Xenograft Model and a Nonhuman Primate
por: Funase, Yuichi, et al.
Publicado: (2021)

(68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report
por: Rauscher, Isabel, et al.
Publicado: (2016)

Temporary Reactive Response of Axillary Lymph Nodes to COVID-19 Vaccination on (18)F-rhPSMA-7.3 PET/CT in Patients with Prostate Cancer
por: Notohamiprodjo, Susan, et al.
Publicado: (2022)

Kinetic analysis and optimisation of (18)F-rhPSMA-7.3 PET imaging of prostate cancer
por: Malaspina, Simona, et al.
Publicado: (2021)

Safety, Biodistribution, and Radiation Dosimetry of (18)F-rhPSMA-7.3 in Healthy Adult Volunteers
por: Tolvanen, Tuula, et al.
Publicado: (2021)

(177)Lu-rhPSMA-10.1 Induces Tumor Response in a Patient With mCRPC After PSMA-Directed Radioligand Therapy With (177)Lu-PSMA-I&T
por: Bundschuh, Ralph A., et al.
Publicado: (2023)

Current role of PSMA-PET imaging in the clinical management of prostate cancer
por: Georgakopoulos, Alexander, et al.
Publicado: (2023)

Whole-body uptake classification and prostate cancer staging in (68)Ga-PSMA-11 PET/CT using dual-tracer learning
por: Capobianco, Nicolò, et al.
Publicado: (2021)

Optimized (68)Ga-Labeled Urea-Based PSMA-Targeted PET Tracers for Prostate Cancer
por: Wu, Yitian, et al.
Publicado: (2022)

Integration of (68)Ga-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study
por: Dewes, Sabrina, et al.
Publicado: (2016)

Introduction of a SiFA Moiety into the D-Glutamate Chain of DOTA-PP-F11N Results in Radiohybrid-Based CCK-2R-Targeted Compounds with Improved Pharmacokinetics In Vivo
por: Holzleitner, Nadine, et al.
Publicado: (2022)

The current status of prostate cancer treatment and PSMA theranostics
por: Uemura, Motohide, et al.
Publicado: (2023)

Novel Preclinical and Radiopharmaceutical Aspects of [(68)Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer
por: Eder, Matthias, et al.
Publicado: (2014)

Day-to-day variability of [(68)Ga]Ga-PSMA-11 accumulation in primary prostate cancer: effects on tracer uptake and visual interpretation
por: olde Heuvel, Judith, et al.
Publicado: (2020)

Impact of (68)Ga-PSMA-PET imaging on target volume definition and guidelines in radiation oncology - a patterns of failure analysis in patients with primary diagnosis of prostate cancer
por: Schiller, K., et al.
Publicado: (2018)

(44)Sc-PSMA-617 for radiotheragnostics in tandem with (177)Lu-PSMA-617—preclinical investigations in comparison with (68)Ga-PSMA-11 and (68)Ga-PSMA-617
por: Umbricht, Christoph A., et al.
Publicado: (2017)

Skeletal (18)F-PSMA-1007 uptake in prostate cancer patients
por: Janssen, Jorinde, et al.
Publicado: (2023)

Preclinical evaluation of [(68)Ga]NOTA-pentixafor for PET imaging of CXCR4 expression in vivo — a comparison to [(68)Ga]pentixafor
por: Poschenrieder, Andreas, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_trbn3f5haorpqcjecuqrdtk3c9